Nucleome Therapeutics Ltd has appointed the investment professional Jonathan Hepple to its board as a non-executive director. Dr Hepple is a strategic advisor to Oxford Sciences Innovation, the founding investor of Nucleome which was launched in 2019 to explore new treatments for disease by decoding the dark matter of the human genome. Dr Hepple is also co-founder and partner of Rosetta Capital. He holds a PhD in cancer research from the University of Cambridge and a bachelor’s degree in biology from the University of Oxford.
Nucleome Therapeutics announced the appointment on 25 May 2021.
Copyright 2021 Evernow Publishing Ltd